Outlook Therapeutics Sells $5M in Stock, Slashes Major Shareholder's Warrant Price by 67%
OTLK has more than doubled off its 52-week low of $0.161 on elevated volume (8.1× avg).
Summary
Outlook Therapeutics announced a $5.0 million registered direct offering of 8.5 million shares at $0.5855 per share to its largest stockholder. More significantly, the company agreed to amend warrants for 15.4 million shares held by this same stockholder, drastically reducing their exercise price from $1.78 to $0.5855 per share. This offering provides needed working capital but is highly dilutive, priced below market. The warrant amendment is a major concession, making substantial future dilution at a deeply discounted price much more likely for existing shareholders. This financing comes amidst the company's ongoing financial distress, including a "going concern" warning and Nasdaq delisting risk. The upcoming special meeting to vote on further dilution and a reverse split remains a critical event.
At the time of this announcement, OTLK was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $87M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.